19 November 2021 LungLife AI, Inc. (the “Company” or “LungLife”) LungLife AI Clinical Laboratory achieves CAP accreditation Independent inspection confirms highest standard of care for laboratory patients LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that its clinical laboratory in Thousand Oaks, California […]
10 November 2021 LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Application LungLife AI (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that a block listing application (the “Block Admission”) has been made to the London Stock Exchange for up to 1,356,139 common shares of US […]
LungLife AI licensure/accreditation information posted here.